Image Credit: Shutterstock
Cipla announced its unaudited consolidated financial results for the quarter ended December 31, 2021. Income from operations has been registered at Rs 5479 crore, EBITDA at Rs 1243 crore and PAT at Rs 729 crore.
The overall India business grew by 13 per cent YoY led by sustained momentum across core therapies and traction in flagship brands; modest contribution from the covid portfolio. The South Africa private business grew 16 per cent YoY growth in ZAR terms; maintains market-beating trajectory in secondary terms. The US business reported $150 million in revenue.
"Our EBITDA margins for the quarter came in at 22.7 per cent and given the YTD traction, we are well placed to close the year in line with our guidance of 22 per cent. We continue our efforts to improve patient access for therapies including covid products and ensuring adequate supply across all our markets," said Umang Vohra, MD and Global CEO, Cipla.
